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Abstract
Lymphocytic esophagitis (LE) is a histologic pattern with no established clinical correlates in the 
majority of patients. The goal of this study was to evaluate the association between non-achalasia 
primary esophageal motility disorders (PMED) and LE. Sixty-nine patients with PMED and 
esophageal biopsies, including 22 with nutcracker esophagus, 33 with ineffective motility and 14 
with diffuse spasm, constituted the study group. The control group consisted of 70 patients with 
severe dysmotility-negative gastroesophageal reflux disease (GERD) requiring referral for Nissen 
fundoplication. To improve the criteria for LE, a lymphocyte reference range at different 
esophageal levels was first established in 17 healthy volunteers. The cutoffs for normal 
intraepithelial lymphocytes (IEL), defined as lymphocyte levels not exceeding mean level + 2 
standard deviations, were set at 62, 46, and 41 lymphocytes per high power field at 0 to 2 cm, 5 
cm, and 10 cm above the gastroesophageal junction, respectively. Predominantly focal 
peripapillary LE was observed in approximately 40% of patients with nutcracker esophagus or 
diffuse spasm and 20% of patients with ineffective motility, in comparison to 4% of patients with 
dysmotility-negative GERD (P < 0.035 versus any subtype of PMED). Overall, LE was strongly 
associated with PMED in multivariate analysis (adjusted odds ratio, 7.93; 95% CI: 2.26, 27.9; 
P=0.001). LE had a chronic course in 56% of the patients with follow-up biopsies. In conclusion, 
LE has a strong association with PMED, suggesting utility of LE in raising the possibility of 
PMED.
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INTRODUCTION
Non-achalasia primary esophageal motility disorders (PEMD), such as nutcracker 
esophagus, ineffective motility, and diffuse spasm, are defined as motility patterns that differ 
significantly from normal variants.(1) The etiology and pathogenesis of PEMD are largely 
unknown and clinical features vary. Moreover, histologic correlates for these conditions have 
not been described, resulting in controversy regarding their significance as specific 
clinicopathological entities.
Lymphocytic esophagitis (LE) is a histologic pattern characterized by high number of 
intraepithelial lymphocytes (IEL) and rare or absent intraepithelial granulocytes.(2–5) 
Peripapillary localization of lymphocytes and spongiosis are also characteristic of LE, and 
were used as additional criteria by some authors.(2, 3) Previous studies report associations 
of LE with achalasia, Crohn’s disease in children, post-ablation status in Barrett esophagus, 
common variable immunodeficiency, lichen planus and some other dermatological disorders.
(3, 6–11) However, in the majority of adult patients with LE clinical correlates have not been 
established.(2–4) We have recently proposed a link between LE and esophageal dismotility 
patterns.(5) Yet, the significance of LE for PEMD, including the prevalence of LE, the 
strength of the association and the natural history of LE remained unknown. The goal of this 
study was to investigate a putative association of LE with PEMD.
Knowledge of the normal range of esophageal IEL is essential for accurate diagnosis of LE. 
However, it has not been yet reported in healthy adult subjects. Therefore, the specific aims 
of our study were, first, to establish normal values for esophageal IEL at different levels of 
the esophagus and, second, to evaluate the prevalence, morphologic features and natural 
history of LE in patients with PEMD.
METHODS
Case Material
A total of 146 cases of diffuse esophageal spasm, nutcracker esophagus and ineffective 
esophageal motility diagnosed using standard manometry were identified through electronic 
medical records of our institution from 2007–2014. Esophageal biopsies were available in a 
subgroup of 69 patients, including 22 with nutcracker esophagus, 33 with ineffective 
motility, and 14 with diffuse spasm.
The control group was derived from 233 patients with severe GERD undergoing endoscopy 
and manometry before referral for Nissen fundoplication at our institution between 2007 and 
2014.The control group included patients with manometry-proven absence of esophageal 
motility disorders and available esophageal biopsies. Individuals with histologic esophagitis 
arising from causes other than GERD were excluded. Of the 77 patients with dysmotility-
negative GERD and esophageal biopsies, 70 qualified for the study. Seven excluded patients 
consisted of 2 patients with mild non-classifiable motility abnormalities, 2 with features of 
Candida esophagitis, 2 with features compatible with eosinophilic esophagitis and 1 with pill 
esophagitis. The study was approved by the Committee for the Protection of Human 
Subjects at Dartmouth College.
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Clinical information
Clinical data was extracted from the electronic medical records of Dartmouth-Hitchcock 
Medical Center and included: demographics, clinical diagnosis, complaints, past medical 
history, endoscopic and manometric findings.
Nutcracker esophagus was defined as a mean distal esophageal amplitude of contraction > 
180 mm Hg. Ineffective motility was defined as hypocontraction in the distal part of the 
esophagus with at least 30% of wet swallows showing any combination of the following 
abnormalities: distal esophagus peristaltic wave amplitude < 30 mmHg; failed peristalsis in 
which the peristaltic wave does not traverse the entire length of the distal esophagus; or 
absent peristalsis. Diffuse esophageal spasm was defined as simultaneous contractions in the 
distal esophagus in ≥ 20% of wet swallows, with amplitude contraction of ≥ 30 mmHg, 
alternating with normal peristalsis.(1)
The vast majority of patients with motility disorders received treatment with one or more of 
the following: proton pump inhibitors, calcium channel blockers, peppermint tea, tricyclic 
antidepressants, botulinum toxin injections, anticholinergics, and/or fundoplication. None of 
the patients received steroids or immunomodulatory drugs.
To ensure proper recording of retrospective data, a uniform electronic data abstraction form 
with data codes and a protocol to resolve ambiguous or conflicting data was created. The 
abstractors (J.P. and M.L.) were blinded to the histologic and immunophenotypic data.
Evaluation of healthy volunteers
Thirty three volunteers, asymptomatic by GERD-Q questionnaire(12) and clinical 
evaluation, were recruited within the hospital staff. Further inclusion criteria included the 
absence of endoscopic or histologic esophagitis and normal esophageal acid exposure. 
Twenty eight subjects completed both unsedated transnasal esophagoscopy with biopsy and 
48-hour wireless Bravo pH monitoring.(13) Normal acid exposure was defined as equal or 
less than 5.6% of total time with pH <4. Seventeen subjects satisfied the inclusion criteria. 
Biopsies were performed using pediatric forceps and consisted of 2 – 4 mucosal fragments 
taken between 0 and 2 cm (gastroesophageal junction), 5 cm (distal esophagus) and 10 cm 
(mid esophagus) from the Z-line. The number of intraepithelial lymphocytes was counted in 
the field of view (400×) with the highest density of lymphocytes using an Olympus BX 41 
microscope with a field number 22 eyepiece, resulting in a 0.237 mm2 field of view. The 
upper limit of normal number of lymphocytes was calculated for each esophageal level as 
the mean count of lymphocytes + 2 standard deviations (SD).
Histologic Evaluation
Biopsies of approximately a half (49%) of PEMD patients were taken from the mid 
esophagus, largely to rule out eosinophilic esophagitis. Biopsies of another half (51%) of 
PEMD patients were taken from the distal esophagus. In patients with dysmotility-negative 
GERD, biopsies were taken from the distal esophagus in 97% of the cases. The following 
histologic features were evaluated in the biopsies: distribution, localization and number of 
IEL, the presence of spongiosis (i.e. intercellular edema) in the area of IEL, and the number 
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of intraepithelial eosinophils and neutrophils. Basal hyperplasia and elongation of stromal 
papillae were noted in biopsies with adequate orientation.(14) LE was defined as a 
lymphocyte count exceeding the upper limit of the normal range (i.e. mean + 2 SD) for a 
given biopsy level and absent or rare intraepithelial granulocytes, arbitrarily defined as no 
more than, on average, one granulocyte for every two fields of view (400×). A single 
lymphoid infiltrate was also considered as LE. Reflux esophagitis was diagnosed on the 
basis of basal hyperplasia, elongated stromal papillae and multiple intraepithelial 
granulocytes (arbitrarily defined as ≥ 1 granulocyte/HPF). Other types of esophagitis, such 
as infectious esophagitis, eosinophilic esophagitis, pill esophagitis, and radiation/
chemotherapy-induced esophagitis were excluded. Two authors (J.P. and M.L.) analyzed 
biopsies independently, and discrepancies were resolved by consensus. As in healthy 
volunteers, lymphocytes were counted in the field of view (400×) in the most affected area. 
Increased lymphocytes were considered focal when present in <50% of the biopsy and 
diffuse when present in ≥50%. They were deemed peripapillary when the lymphocytic 
infiltrate was centered on a stromal papilla and there was an abrupt transition of the density 
of lymphocytes from the peripapillary area to the mainly devoid of lymphocytes 
interpapillary area. Lymphocytes were considered peripapillary/interpapillary when they 
extended into the interpapillary space as a gradient with decreasing density. Lymphocytes 
were considered diffuse when no relation of lymphocytes to the stromal papillae was 
present. Spongiosis was defined as either irregular rounded dilatation or widening of the 
spaces between neighboring epithelial cells. Spongiosis was considered prominent when the 
space between the epithelial cells was equal to or greater than the width of the epithelial cell 
nucleus; it was considered moderate when the intercellular space was less than the width of 
the epithelial cell nucleus.
CD4 and CD8 Immunohistochemistry
Routine CD4 and CD8 immunohistochemistry was performed using Bond Polymer Refine 
Detection staining reagents (Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, UK) 
and Bond III autostainer (Leica Microsystems). The following primary antibodies were 
used: anti-CD4 antibody at a 1:100 dilution (clone SP35, Cell Marque, Rocklin, CA, USA) 
and anti-CD8 BondTM ready-to-use antibody (clone 4b11, Leica Biosystems Newcastle Ltd, 
Newcastle Upon Tyne, UK). CD4 T-cells and CD8 T-cells were counted in the same field of 
view (400×) where lymphocytes were counted. A CD4:CD8 ratio > 1 indicated a 
predominance of CD4 T-cells; a ratio ≤ 1 indicated a predominance of CD8 T-cells.
Statistics
The distributions of baseline characteristics were compared between the groups using non-
parametric Wilcoxon rank-sum tests for continuous variables and χ2 tests for categorical 
variables. Multivariate logistic regression models were used to estimate odds ratios and the 
associated 95% confidence intervals (CIs). Potential confounding covariates included: age, 
sex, dysphagia, reflux, presence of normal esophagus, irregular Z-line/evidence of Barret 
esophagus, and ulcer/stricture. Only covariates that produced a >10% change in the odds 
ratio were included in the fully adjusted models.(15) Statistical analyses were performed 
using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA) and STATA – version 
12 (StataCorp LP, College Station, TX, USA). P values are from two-sided tests.
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RESULTS
Lymphocyte counts in healthy volunteers
Seventeen asymptomatic volunteers had normal endoscopic and histologic findings and 
normal esophageal acid exposure (Table 1). The biopsies from these volunteers had a normal 
distribution of IEL. The mean ± SD of lymphocyte counts were: 26 ± 18 at 0 – 2 cm 
(gastroesophageal junction), 24 ± 11 at 5 cm (distal esophagus) and 23 ± 9 at 10 cm (mid-
esophagus). The cut-offs for high IEL (i.e. mean + 2 SD) were estimated as: 62, 46 and 41 at 
0 to 2 cm, 5 cm, and 10 cm from the gastroesophageal junction, respectively. In 12 patients, 
CD4 and CD8 immunohistochemistry was performed on biopsies at 10 cm. CD8 T-cells 
outnumbered CD4 T-cells in 83% (10/12) of the subjects and the mean CD4:CD8 ratio was 
0.56 ± 0.43, indicating that esophageal IEL are CD8-predominant in healthy individuals.
Clinico-endoscopic features in patients with PEMD and dysmotility –negative GERD
Table 2 presents demographic, clinical and endoscopic characteristics of the patients. 
Patients with PEMD were more likely than the controls with dysmotility-negative GERD to 
experience dysphagia, 51% (35/69) versus 11% (8/70), and present with a normal esophagus 
during endoscopy, 45% (31/69) versus 21% (15/70). However, PEMD patients were less 
likely than GERD controls to report reflux/heartburn symptoms, 35% (24/69) versus 56% 
(39/70), and have endoscopic evidence of an irregular Z-line/possible Barrett esophagus, 
26 % (18/69) versus 46% (32/70), or ulcer/stricture, 0 versus 8% (6/70). Case and control 
patients were similar with regard to age, sex, prevalence of chest/epigastric pain, and 
endoscopic evidence of rings/furrows, esophagitis, and hiatal hernia/Schatzki ring. Overall, 
the data demonstrate significant clinico-endoscopic differences between patients with PEMD 
and dysmotility-negative GERD.
LE shows strong association with PEMD
LE was observed in 45% (10/22), 21% (7/33) and 36% (5/14) of patients with nutcracker 
esophagus, ineffective motility and diffuse esophageal spasm, respectively (Fig. 1). The rest 
of the patients with high IEL had a pattern of reflux esophagitis: 9% (2/22) with nutcracker 
esophagus, 18% (6/33) with ineffective motility, and 14% (2/14) with diffuse spasm (Table 
3). In contrast, LE was seen only in 6% (4/70) of patients with dysmotility–negative GERD 
(P < 0.035, versus any type of the PMED) (Table 3). LE was strongly associated with PEMD 
(odds ratio, 7.72, 95% CI: 2.50, 23.9; Table 4). The association remained significant upon 
further adjustment for age, sex, dysphagia, reflux, and presence of normal esophagus 
(adjusted odds ratio, 7.93, 95% CI: 2.26, 27.9). The associations between LE and specific 
PEMD (nutcracker esophagus, ineffective motility, or diffuse spasm) were also positive, 
albeit with wide confidence intervals due to the small sample sizes, and the association was 
strongest for the subset of patients with nutcracker esophagus (Table 4).
Morphologic and immunophenotypic features of LE
LE was focal in 82% (18/22) and peripapillary in 68% (15/22) of patients with PMED 
(Table 5). Prominent spongiosis was present in a minority of patients, 32% (7/22). Similarly, 
in control patients with dysmotility-negative GERD, LE was focal in 75% (3/4) of the 
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patients and was peripapillary in 50% (2/4). However, there were no cases (0/4) with 
prominent spongiosis.
LE demonstrated CD4-predominant IEL in 50% (5/10), 86% (6/7) and 60% (3/5) of patients 
with nutcracker esophagus, ineffective motility and diffuse spasm, respectively. Thus, the 
majority of patients with PMED, 64% (14/22), had CD4-predominant T-cells (Table 5). In 
contrast, only 25% (1/4) patients with LE and dysmotility–negative GERD had CD4-
predominant IEL.
Follow up data in patients with PMED
Six of 22 (27%) patients with nutcracker esophagus had follow-up biopsies (mean ± SD 
follow up period 4.0 ± 4.1 years). Three of the six followed patients had LE on initial biopsy, 
and one of three (33%) demonstrated the same 7 years after the index biopsy. This patient 
was treated with a calcium channel blocker diltiazem and a proton pump inhibitor 
esomeprazole. The other two patients, in whom LE was not present on follow up, received 
proton pump inhibitors omeprazole and pantoprazole. The three patients who had initial 
lymphocyte counts in the normal range continued to have normal lymphocyte levels at 
follow-up.
Ten of 33 (30%) patients with ineffective motility had follow-up biopsies (mean ± SD follow 
up period 2.5 ± 2.0 years). In 5 of the followed patients who had LE on initial biopsy, 3 
(60%) demonstrated LE after 0.5, 1 and 5 years of follow-up, respectively. All 3 latter 
patients received esomeprazole, and, in addition, one received botulinum toxin injections 
and one received peppermint. The other two patients, in whom LE was not present on follow 
up, received proton pump inhibitors esomeprazole and pantoprazole. In 5 of the followed 
patients with normal numbers of IEL on the original biopsy, one patient had LE 4 years after 
the index biopsy. The patient received sublingual nitroglycerin.
One patient with diffuse spasm and LE had a follow-up biopsy, which also demonstrated LE 
8 years after the index biopsy. The patient was taking omeprazole during the follow up 
period. Overall, the data suggest that 56% (5/9) of patients with PEMD and LE continued to 
have LE on follow up. Thirteen percent (1/8) of patients with PMED and no evidence of LE 
on index biopsy demonstrated LE on follow up. These data suggests a chronic course of LE 
in a significant proportion of patients with PMED.
DISCUSSION
Despite wide acceptance of the term “LE” its histologic criteria remain insufficiently 
defined. Previously published data on normal numbers of IEL were derived from patients 
with upper gastrointestinal symptoms and may not be generalizable for the broader patient 
population.(16, 17) Thus, either qualitative assessment or arbitrary quantitative lymphocyte 
thresholds are in use. The qualitative assessment can reliably detect only prominent forms of 
LE. Therefore, knowledge of the normal range of IEL is essential for comprehensive study 
of the spectrum of LE.
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In this study, we first evaluated the range of IEL in healthy volunteers and for the first time, 
to our knowledge, established upper cut-offs for normal content of the IEL at different levels 
of the esophagus in adult subjects. We then applied this data to identify LE in patients with 
PEMD and found that nearly half of the patients with PMED had high IEL in comparison to 
only 10% of patients with dysmotility-negative GERD. More specifically, about 40% of the 
patients with nutcracker esophagus or diffuse spasm and approximately 20% of patients with 
inefficient motility demonstrated LE characterized predominantly by focal (sometimes 
single) peripapillary lymphoid infiltrates. The true proportion of patients with LE is likely 
higher, because randomly taken biopsies may miss focal lymphoid infiltrates. Importantly, in 
multivariate analyses, patients with PMED had approximately eight times the odds of having 
LE relative to patients without motility disorders, suggesting a strong association.
More than a half (56%) of patients with PEMD and LE continued to have LE on follow up, 
consistent with a chronic condition. In addition, one of the patients with PMED 
demonstrated LE only on the follow up biopsy. It remains uncertain whether LE in this 
patient was newly developed. Focal LE could disappear or manifest in serially performed 
biopsies due the tendency to be missed in randomly performed biopsies. Alternatively, LE 
could wax and wane.
Nearly two thirds of all patients with PMED and LE had a predominance of CD4 T-cells. We 
also noted an association between CD4-predominant LE and motility abnormalities in a 
previous study, however the significance of CD4-predominant lymphocytes remains unclear.
(5) There is limited literature on CD4 T-lymphocytes in the esophageal mucosa. In normal 
conditions, CD4 T-cells reside mainly in the lamina propria.(18) In pathologic conditions, 
CD4-predominant LE was recently reported in achalasia,(19) and high levels of 
intraepithelial CD4-predominant T-cells were observed in Candida esophagitis.(20) In 
contrast, IEL are predominantly CD8 T-cells in normal individuals,(18) which is supported 
by our findings of intraepithelial CD8-predominant T-lymphocytes in 83% of studied 
healthy volunteers.
The etiological relevance of LE in PMED warrants further consideration. First, it could be 
speculated that to cause motility disturbances, lymphocytic inflammation should involve 
esophageal smooth muscle, either directly or through its innervation, and that LE is too 
superficial to have such an effect. Because LE is associated with achalasia (and its myenteric 
lymphocytic inflammation),(8, 19) it is possible that LE of PMED is also an indicator of 
deeper inflammatory process. That the pathogenesis of PMED and achalasia may be related, 
is supported by transition of nutcracker esophagus(21, 22) and diffuse spasm(23, 24) to 
achalasia and by myenteric lymphocytic inflammation in the distal esophagus of 23% (3/13) 
of patients with nutcracker esophagus.(25)
A second consideration is the fact that LE was associated with both hypocontractile (i.e. 
ineffective motility) and hypercontractile motility patterns (i.e. diffuse esophageal spasm and 
nutcracker esophagus). While the heterogeneity of motility patterns is noteworthy, there are 
examples of a single entity, such as eosinophilic esophagitis, demonstrating both 
hypercontractile and hypocontractile motility patterns.(26) Therefore, heterogeneity of 
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motility patterns does not preclude compatibility with LE. Finally, reverse causality, where 
PMED cause LE, remains a possibility.
Our study has several limitations. The study is retrospective and selection bias cannot be 
excluded. Because endoscopic biopsies are not standard of care in GERD or PMED, not all 
patients had histologic evaluation, which could also introduce bias. Motility abnormalities 
were evaluated only with the help of standard manometry. In addition, due to the difficulty 
of obtaining follow-up biopsies, we were unable to fully investigate the extent to which LE 
remained chronic. These deficits could be corrected in future studies that employ prospective 
designs and high resolution manometry. Finally, because the pathophysiological mechanisms 
underlying LE and PMED are uncertain, residual confounding by an unmeasured marker 
remains possible.
In conclusion, our data suggest a strong association between PMED and LE. LE has a 
chronic course in many patients with PMED. Presence of LE in biopsies may be helpful in 
raising the possibility of PMED.
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Figure 1. 
A – C, Lymphocytic esophagitis in a biopsy from a patient with nutcracker esophagus. A, 
hematoxylin and eosine stain. B, immunohistochemistry demonstrating CD4 T-cells. C, 
immunohistochemistry demonstrating CD8 T-cells.
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